Jan G M Klijn
Overview
Explore the profile of Jan G M Klijn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
7957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollestelle A, Peeters J, Smid M, Timmermans M, Verhoog L, Westenend P, et al.
Breast Cancer Res Treat
. 2013 Jan;
138(1):47-57.
PMID: 23338761
Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a spindle cell morphology in combination with loss of E-cadherin and upregulation of mesenchymal markers. However, by studying...
2.
Heijnsdijk E, Warner E, Gilbert F, Tilanus-Linthorst M, Evans G, Causer P, et al.
Cancer Epidemiol Biomarkers Prev
. 2012 Jun;
21(9):1458-68.
PMID: 22744338
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using MRI because of their very high cancer risk and the high sensitivity of MRI in detecting invasive...
3.
Riaz M, Berns E, Sieuwerts A, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, et al.
Breast Cancer Res Treat
. 2011 Jul;
133(3):843-51.
PMID: 21748294
To understand the biology of low-risk breast cancer alleles, and to investigate whether these loci also contribute to disease progression that was once established, we examined the association of SNPs...
4.
Nagel J, Peeters J, Smid M, Sieuwerts A, Wasielewski M, de Weerd V, et al.
Breast Cancer Res Treat
. 2011 May;
132(2):439-48.
PMID: 21614566
CHEK2 1100delC is a moderate-risk cancer susceptibility allele that confers a high breast cancer risk in a polygenic setting. Gene expression profiling of CHEK2 1100delC breast cancers may reveal clues...
5.
Hamberg P, Bos M, Braun H, Stouthard J, van Deijk G, Erdkamp F, et al.
Clin Breast Cancer
. 2011 May;
11(2):103-13.
PMID: 21569996
Background: Because chemotherapy for metastatic breast cancer (MBC) is associated with relevant toxicity, sequential monotherapy trastuzumab followed by cytotoxic therapy at disease progression might be an attractive approach. Methods: In...
6.
Rijnsburger A, Obdeijn I, Kaas R, Tilanus-Linthorst M, Boetes C, Loo C, et al.
J Clin Oncol
. 2010 Nov;
28(36):5265-73.
PMID: 21079137
Purpose: The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers...
7.
Wasielewski M, Out A, Vermeulen J, Nielsen M, van den Ouweland A, Tops C, et al.
Breast Cancer Res Treat
. 2010 Mar;
124(3):635-41.
PMID: 20191381
Homozygous and compound heterozygous MUTYH mutations predispose for MUTYH-associated polyposis (MAP). The clinical phenotype of MAP is characterised by the multiple colorectal adenomas and colorectal carcinoma. We previously found that...
8.
9.
Wasielewski M, Riaz M, Vermeulen J, van den Ouweland A, Labrijn-Marks I, Olmer R, et al.
Breast Cancer Res Treat
. 2009 Nov;
123(2):315-20.
PMID: 19924528
Germline mutations in the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 predispose to Lynch syndrome (also known as hereditary non-polyposis colorectal cancer). Recently, we have shown that the CHEK2...
10.
Obdeijn I, Loo C, Rijnsburger A, Wasser M, Bergers E, Kok T, et al.
Breast Cancer Res Treat
. 2009 Oct;
119(2):399-407.
PMID: 19876732
In order to assess the characteristics of malignant breast lesions those were not detected during screening by MR imaging. In the Dutch MRI screening study(MRISC), a non-randomized prospective multicenter study,women...